Inclusion Criteria:

          -  At least 18 years of age;

          -  Histopathologically proven adenocarcinoma of the prostate:

               -  Localized cancer;

               -  Subjects with tumors classified as <T3 per TNM classification, Gleason score≥ 6;

          -  Prostate tumor must be able to be visualized on mpMRI;

          -  Already considered to be candidate for radical prostatectomy;

          -  Considered appropriate for treatment with paclitaxel therapy;

          -  Laboratory requirements:

               -  WBC >2500/mm3

               -  Neutrophil >1500/mm3

               -  Hemoglobin >10 mg/dL

               -  Platelet >100,000/ mm3

               -  AST and ALT <2.5 x ULN

               -  Total bilirubin <1.5 x ULN

               -  Calculated creatinine clearance ≥ 30 ml/min

               -  Normal PT/INR and PTT;

          -  ECOG of 0 or 1;

          -  International Prostate Symptom Score (I-PSS) less than or equal to 20;

          -  If sexually active, willing to use double condoms from time of NanoPac injection until
             prostatectomy;

          -  Agree to all study procedures and provide signed informed consent;

        Exclusion Criteria:

          -  Evidence of locally advanced or metastatic disease;

          -  Prostate size ≥ 50 cc;

          -  Prior prostatectomy, including surgery for any benign condition (such as TURP);

          -  Anticipated use of concomitant chemotherapy (other than the protocol specified
             agents), immunotherapy, or systemic use of hormonal therapy (such as GnRH analogs,
             antiandrogens, androgen receptor inhibitors, and 5-α reductase inhibitors) while on
             study prior to surgery;

          -  Treatment with a prior investigational medication within 30 days of first dose of
             study agent;

          -  Any previous local treatment of the prostate (e.g. radiation, HIFU, cryotherapy, Focal
             Irreversible Electroporation, Photodynamic Therapy, Laser Induced Thermometry);

          -  Any other condition (e.g., psychiatric disorder) that, in the opinion of the
             Investigator, may interfere with the subject's ability to comply with the study
             requirements or visit schedule;

          -  Known sensitivity to any of the study agent components;

          -  History of prior malignancy that has not been in remission for >5 years, with the
             exception of basal cell or squamous cell carcinoma.